Apolipoprotein C2 (APOC2) Antibody

Este producto es parte de APOC2 - Apolipoprotein C2
Product Graph
299€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Apolipoprotein C2 (APOC2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx130650
tested applications
WB, IHC, IF/ICC

Description

Apolipoprotein C2 Antibody is a Rabbit Polyclonal against Apolipoprotein C2.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Apolipoprotein C2 (APOC2)
Host
Rabbit
Reactivity
Guinea pig
Recommended Dilution
WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Purification
Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Alias
APOC2, APO-CII, APOC-II, apolipoprotein C2,Apolipoprotein C-II
Background
Antibody anti-APOC2
Status
RUO

Descripción

APOC2 is a key component of VLDL and chylomicrons, playing an essential role in triglyceride metabolism as an activator of lipoprotein lipase (LPL). APOC2 is primarily synthesized in the liver and secreted into the plasma, where it facilitates the hydrolysis of triglycerides in chylomicrons and VLDL into free fatty acids and glycerol for energy production or storage. A deficiency or mutation in the APOC2 gene leads to familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by elevated triglyceride levels, severe hyperlipidemia, and recurrent pancreatitis. APOC2 levels are tightly regulated to maintain lipid balance, as excess or reduced APOC2 activity can disrupt triglyceride clearance and promote atherosclerosis. APOC2 functions cooperatively with other apolipoproteins, such as APOA5 and APOE, to regulate lipid metabolism. Therapeutic strategies targeting APOC2 pathways are being explored to improve triglyceride clearance and reduce cardiovascular risk in individuals with dyslipidemia.

Related Products

EH0619

Human APOC2 (Apolipoprotein C-II) ELISA Kit

Ver Producto
EMK0235

Monkey APOC2 (Apolipoprotein C-II) ELISA Kit

Ver Producto
P4437

Recombinant Human APOC2

Ver Producto